Open Access. Powered by Scholars. Published by Universities.®
- Discipline
Articles 1 - 3 of 3
Full-Text Articles in Medicine and Health Sciences
Metabotropic Glutamate Receptor Subtype 5 Is Reduced In Schizophrenia Subjects With Comorbid Major Depression And Unchanged Following Antipsychotic Drug Treatment, N Jimenez, Xu-Feng Huang, C Deng, K Newell
Metabotropic Glutamate Receptor Subtype 5 Is Reduced In Schizophrenia Subjects With Comorbid Major Depression And Unchanged Following Antipsychotic Drug Treatment, N Jimenez, Xu-Feng Huang, C Deng, K Newell
Xu-Feng Huang
Abstract of a paper that presented at the Australian Neuroscience Society 32nd Annual meeting.
Neuregulin-1 Signalling And Antipsychotic Treatment: Potential Therapeutic Targets In A Schizophrenia Candidate Signalling Pathway, Chao Deng, Bo Pan, Martin Engel, Xu-Feng Huang
Neuregulin-1 Signalling And Antipsychotic Treatment: Potential Therapeutic Targets In A Schizophrenia Candidate Signalling Pathway, Chao Deng, Bo Pan, Martin Engel, Xu-Feng Huang
Xu-Feng Huang
Identifying the signalling pathways underlying the pathophysiology of schizophrenia is an essential step in the rational development of new antipsychotic drugs for this devastating disease. Evidence from genetic, transgenic and post-mortem studies have strongly supported neuregulin-1 (NRG1)-ErbB4 signalling as a schizophrenia susceptibility pathway. NRG1-ErbB4 signalling plays crucial roles in regulating neurodevelopment and neurotransmission, with implications for the pathophysiology of schizophrenia. Post-mortem studies have demonstrated altered NRG1-ErbB4 signalling in the brain of schizophrenia patients. Antipsychotic drugs have different effects on NRG1-ErbB4 signalling depending on treatment duration. Abnormal behaviours relevant to certain features of schizophrenia are displayed in NRG1/ErbB4 knockout mice or …
Structural Contributions Of Antipsychotic Drugs To Their Therapeutic Profiles And Metabolic Side Effects, Somayeh Jafari, Francesca Fernandez-Enright, Xu-Feng Huang
Structural Contributions Of Antipsychotic Drugs To Their Therapeutic Profiles And Metabolic Side Effects, Somayeh Jafari, Francesca Fernandez-Enright, Xu-Feng Huang
Xu-Feng Huang
Antipsychotic drugs have various neuropharmacological properties as a result of their structural diversity. Despite their therapeutic benefits, most of the prescribed atypical antipsychotics can induce severe side effects, including weight gain, type II diabetes mellitus, and cardiovascular diseases. Among the developed atypical antipsychotic agents, tetracyclic dibenzodiazepine and thienobenzodiazepine compounds, particularly clozapine and olanzapine, are associated with the greatest weight gain and metabolic disturbances. However, the unique chemical structure of these compounds causes the low risk of side effects reported for typical antipsychotics (e.g. extrapyramidal symptoms and tardive dyskinesia). This report reviews the recent discovery of the potential role of the …